Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BAY 1747846
- Development stage
- Unknown
- Lead developer
- Bayer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
BAY 1747846 is an orally bioavailable small molecule inhibitor of coagulation Factor XIa (FXIa) developed by Bayer. Factor XIa is a key protease in the intrinsic pathway of the coagulation cascade, and its inhibition is hypothesized to provide antithrombotic efficacy with a lower risk of bleeding compared to traditional anticoagulants that target the common pathway (such as Factor Xa or thrombin). The drug has been investigated in Phase 1 clinical trials to assess its safety, tolerability, and pharmacokinetics in healthy volunteers, primarily for the potential prevention and treatment of thromboembolic disorders.
02
Targets
F11 (Coagulation Factor XI)
Beyond the preview
Go deeper on BAY 1747846.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BAY 1747846.